Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Retained Earnings (2017 - 2025)

Historic Retained Earnings for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $1.4 million.

  • Innate Pharma's Retained Earnings rose 25453.7% to $1.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.4 million, marking a year-over-year increase of 25453.7%. This contributed to the annual value of $28852.1 for FY2024, which is 9458.27% down from last year.
  • Per Innate Pharma's latest filing, its Retained Earnings stood at $1.4 million for Q2 2025, which was up 25453.7% from $28852.1 recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Retained Earnings registered a high of $1.4 million during Q2 2025, and its lowest value of $28852.1 during Q4 2024.
  • Over the past 5 years, Innate Pharma's median Retained Earnings value was $532590.3 (recorded in 2023), while the average stood at $663796.4.
  • As far as peak fluctuations go, Innate Pharma's Retained Earnings surged by 28232.57% in 2023, and later tumbled by 9458.27% in 2024.
  • Innate Pharma's Retained Earnings (Quarter) stood at $521650.8 in 2021, then surged by 60.18% to $835582.5 in 2022, then plummeted by 36.26% to $532590.3 in 2023, then crashed by 94.58% to $28852.1 in 2024, then skyrocketed by 4584.45% to $1.4 million in 2025.
  • Its Retained Earnings was $1.4 million in Q2 2025, compared to $28852.1 in Q4 2024 and $381218.2 in Q2 2024.